Evidence map›Paper›PMID 36578000›Full record

ArticleChinese medicine2022

Effect of ginsenoside compound K on alleviating colitis via modulating gut microbiota.

Li Wang, Li Shao, Man-Yun Chen, Lin Wang, Wei Zhang, Feng-Bo Tan, Wei-Hua Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. The application ofAnnals of translational medicine · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Li WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Li ShaoDepartment of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410128, China.
Man-Yun ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Lin WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Feng-Bo TanDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China. fengbotan@csu.edu.cn.
Wei-Hua HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China. endeavor34852@csu.edu.cn.ORCID http://orcid.org/0000-0003-4167-8304
Central South University · CNHunan University of Traditional Chinese Medicine · CN

Funding

National Natural Science Foundation of China 82074000
6 · The paper itself

Abstract

backgroundGinsenoside compound K (GC-K) potentially alleviates ulcerative colitis involved in gut microbiota, which is significantly associated with the occurrence and development of colitis. However, the effect and mechanism of GC-K on anti-colitis in relation to gut microbiota are not clear. This study focused on the prevention and mechanism of GC-K on Dextran sulfate sodium (DSS)-induced colitis of mice pertinent to gut microbiota.

methodsDSS was used to establish a chronic colitis mouse model. Body weight analysis, colon length measurement, HE staining, and inflammatory factors levels were processed in animal experiments. Flow cytometry was employed to analyze Th17/Treg cells in the mouse spleen and blood. 16S rRNA sequencing was utilized to analyze gut microbiota. Fecal microbiota transplantation (FMT) experiment was employed to verify the anti-colitis efficacy of GC-K by reshaping gut microbiota.

resultsGC-K significantly relieved colitis-related symptoms due to decreased disease activity index (DAI) scores, spleen weight, and increased colon length. Additionally, the tight junction proteins were increased, and the pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1β and IL-17, were decreased after GC-K treatment. Furthermore, Bacteroides spp. significantly increased after modeling. Moreover, FMT experiments confirmed that GC-K-driven gut microbiota greatly relieved DSS-induced colitis.

conclusionGC-K alleviated colitis via the modulation of gut microbiota.

Indexed as

ColitisFMTGinsenoside compound KGut microbiota

Identifiers

PMID36578000
PMCPMC9795722
OpenAlexW4313339702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.